Company · founded 2007

Aronora (United States)

Portland, United States · aronorabio.com

Manage this page

Citations, last 5 years: 368
Works, last 5 years: 38
h-index: 51
Scientists listed: 1
Grants since 2016: 26

Grants received

2024–2025 · research · R44

Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis

Christina U Lorentz · Aronora (United States) · funded by National Institutes of Health

$494kCentral Venous Catheters and Hemodialysis

2024–2027 · research · R44

Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis

Christina U Lorentz · Aronora (United States) · funded by National Institutes of Health

$1.1M

2023–2024 · research · R44

Contact Pathway Inhibitor to Prevent Vascular Access Failure

Christina U Lorentz · Aronora (United States) · funded by National Institutes of Health

$998.5kCentral Venous Catheters and Hemodialysis

2023–2026 · research · R44

Contact Pathway Inhibitor to Prevent Vascular Access Failure

Christina U Lorentz · Aronora (United States) · funded by National Institutes of Health

$1.5MCentral Venous Catheters and Hemodialysis

2023–2027 · research · R44

Contact Pathway Inhibitor to Prevent Vascular Access Failure

Christina U Lorentz · Aronora (United States) · funded by National Institutes of Health

$1.3M

2022–2026 · research · R44

Thrombopoietin Targeting in Myeloproliferative Neoplasms

Christina U Lorentz · Aronora (United States) · funded by National Institutes of Health

$669.1kMyeloproliferative Neoplasms: Diagnosis and Treatment

2022–2025 · research · R44

Thrombopoietin Targeting in Myeloproliferative Neoplasms

Christina U Lorentz · Aronora (United States) · funded by National Institutes of Health

$700.3kMyeloproliferative Neoplasms: Diagnosis and Treatment

2022–2023 · research · R44

Thrombopoietin Targeting in Myeloproliferative Neoplasms

Christina U Lorentz · Aronora (United States) · funded by National Institutes of Health

$301.8kMyeloproliferative Neoplasms: Diagnosis and Treatment

2020–2022 · research · R43

E-WE thrombin for prevention of post-traumatic osteoarthritis

Brandon D Markway · Aronora (United States) · funded by National Institutes of Health

$225kBlood Coagulation and Thrombosis Mechanisms

2019–2025 · research · R44

Antithrombotic Protein C Activator for Hemodialysis

Erik Ian Tucker · Aronora (United States) · funded by National Institutes of Health

$999.4k

2019–2024 · research · R44

Antithrombotic Protein C Activator for Hemodialysis

Erik Ian Tucker · Aronora (United States) · funded by National Institutes of Health

$999.4k

2019–2024 · research · R44

Antithrombotic Protein C Activator for Hemodialysis

Erik Ian Tucker · Aronora (United States) · funded by National Institutes of Health

$998.3k

2019–2021 · research · R44

Antithrombotic Protein C Activator for Hemodialysis

Erik Ian Tucker · Aronora (United States) · funded by National Institutes of Health

$1.5M

2019–2021 · research · R44

Antithrombotic Protein C Activator for Hemodialysis

Erik Ian Tucker · Aronora (United States) · funded by National Institutes of Health

$994.1k

2017 · research · R44

Therapeutic factor XI blockade for sepsis

Andras Gruber · Aronora (United States) · funded by National Institutes of Health

$359.7kCoagulation, Bradykinin, Polyphosphates, and Angioedema

2016–2019 · research · R44

HLS- Factor XII Inhibitor for Surface Initiated Thrombosis

Erik Ian Tucker · Aronora (United States) · funded by National Institutes of Health

$299.6kCoagulation, Bradykinin, Polyphosphates, and Angioedema

2016–2023 · research · R44

Factor XII Inhibitor for Surface Initiated Thrombosis

Christina U Lorentz · Aronora (United States) · funded by National Institutes of Health

$999.9k

2016–2020 · research · R44

HLS- Factor XII Inhibitor for Surface Initiated Thrombosis

Erik Ian Tucker · Aronora (United States) · funded by National Institutes of Health

$963.1kCoagulation, Bradykinin, Polyphosphates, and Angioedema

2016–2024 · research · R44

Factor XII Inhibitor for Surface Initiated Thrombosis

Christina U Lorentz · Aronora (United States) · funded by National Institutes of Health

$953.5k

2016–2019 · research · R44

HLS- Factor XII Inhibitor for Surface Initiated Thrombosis

Erik Ian Tucker · Aronora (United States) · funded by National Institutes of Health

$998.8kCoagulation, Bradykinin, Polyphosphates, and Angioedema

2016–2023 · research · R44

Factor XII Inhibitor for Surface Initiated Thrombosis

Christina U Lorentz · Aronora (United States) · funded by National Institutes of Health

$982k

2013–2020 · research · R44

Therapeutic Protein C Activator for Myocardial Ischemia

Erik Ian Tucker · Aronora (United States) · funded by National Institutes of Health

$998.1kBlood Coagulation and Thrombosis Mechanisms

2013–2020 · research · R44

Therapeutic Protein C Activator for Myocardial Ischemia

Erik Ian Tucker · Aronora (United States) · funded by National Institutes of Health

$999.3kBlood Coagulation and Thrombosis Mechanisms

2013–2021 · research · R44

Therapeutic Protein C Activator for Myocardial Ischemia

Erik Ian Tucker · Aronora (United States) · funded by National Institutes of Health

$998.8kBlood Coagulation and Thrombosis Mechanisms

2011–2021 · research · R44

Factor XI inhibitor for thrombosis

Christina U Lorentz · Aronora (United States) · funded by National Institutes of Health

$999.5kCoagulation, Bradykinin, Polyphosphates, and Angioedema

2011–2020 · research · R44

Factor XI inhibitor for thrombosis

Christina U Lorentz · Aronora (United States) · funded by National Institutes of Health

$999.5kCoagulation, Bradykinin, Polyphosphates, and Angioedema